1. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulintherapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6–year study. Diabetes Res Clin Pract 1995; 28:103–17.
2. UK Prospective Diabetes Study (UKPDS). Group Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lanсet 1998; 352 (9131): 837–53.
3. Turner RC et al. The UK Prospective Diabetes Study Group: glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–12.
4. Шестакова М.В., Зилов А.В. Выбор оптимальной сахароснижающей терапии у пациентов с сахарным диабетом в дебюте заболевания. Consilium Medicum. 2010; 12 (12): 5–10.
5. Верткин А.Л., Скотников А.С., Магомедова А.Ю. и др. Терапия коморбидного больного сахарным диабетом: фокус на гипогликемию. Лечащий врач. 2013; 3: 7–10.
6. Veterans Affairs Diabetes Trial Study Group. Ethnicity, race, and clinically significant macular edema. Diabetes Res Clin Pract 2009; 86 (2): 104–10.
7. Action to Control Cardiovascular Risk in Diabetes Study Group. Rationale and design for the blood pressure intervention. Am J Cardiol 2007; 99 (Suppl.): 44i–55i.
8. Dunne N, Viggiani MT, Pardo S et al. Accuracy Evaluation of CONTOURR PLUS Compared With Four Blood Glucose Monitoring Systems. 2015.
9. Управление сахарным диабетом: самоконтроль гликемии как важная составляющая терапии. Consilium Medicum. 2013; 15 (4): 60–2.